Suppr超能文献

在假对称二肽类似物中,将恶唑烷酮作为P2/P2'配体的HIV-1蛋白酶抑制剂的设计与合成。

Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres.

作者信息

Reddy G S Kiran Kumar, Ali Akbar, Nalam Madhavi N L, Anjum Saima Ghafoor, Cao Hong, Nathans Robin S, Schiffer Celia A, Rana Tariq M

机构信息

Chemical Biology Program and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA.

出版信息

J Med Chem. 2007 Sep 6;50(18):4316-28. doi: 10.1021/jm070284z. Epub 2007 Aug 16.

Abstract

A series of novel HIV-1 protease inhibitors based on two pseudosymmetric dipeptide isosteres have been synthesized and evaluated. The inhibitors were designed by incorporating N-phenyloxazolidinone-5-carboxamides into the hydroxyethylene and (hydroxyethyl)hydrazine dipeptide isosteres as P2 and P2' ligands. Compounds with (S)-phenyloxazolidinones attached at a position proximal to the central hydroxyl group showed low nM inhibitory activities against wild-type HIV-1 protease. Selected compounds were further evaluated for their inhibitory activities against a panel of multidrug-resistant protease variants and for their antiviral potencies in MT-4 cells. The crystal structures of lopinavir (LPV) and two new inhibitors containing phenyloxazolidinone-based ligands in complex with wild-type HIV-1 protease have been determined. A comparison of the inhibitor-protease structures with the LPV-protease structure provides valuable insight into the binding mode of the new inhibitors to the protease enzyme. Based on the crystal structures and knowledge of structure-activity relationships, new inhibitors can be designed with enhanced enzyme inhibitory and antiviral potencies.

摘要

基于两种伪对称二肽类似物合成并评估了一系列新型HIV-1蛋白酶抑制剂。这些抑制剂是通过将N-苯基恶唑烷酮-5-羧酰胺作为P2和P2'配体引入到羟乙烯和(羟乙基)肼二肽类似物中而设计的。在靠近中心羟基的位置连接有(S)-苯基恶唑烷酮的化合物对野生型HIV-1蛋白酶表现出低纳摩尔级的抑制活性。对选定的化合物进一步评估了它们对一组多药耐药蛋白酶变体的抑制活性以及它们在MT-4细胞中的抗病毒效力。已确定洛匹那韦(LPV)以及两种含有基于苯基恶唑烷酮配体的新型抑制剂与野生型HIV-1蛋白酶复合物的晶体结构。将抑制剂-蛋白酶结构与LPV-蛋白酶结构进行比较,为新抑制剂与蛋白酶的结合模式提供了有价值的见解。基于晶体结构和构效关系知识,可以设计出具有增强酶抑制和抗病毒效力的新抑制剂。

相似文献

5
Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.
J Med Chem. 2020 Aug 13;63(15):8296-8313. doi: 10.1021/acs.jmedchem.0c00529. Epub 2020 Aug 3.
6
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
J Med Chem. 2019 Sep 12;62(17):8062-8079. doi: 10.1021/acs.jmedchem.9b00838. Epub 2019 Aug 21.
9
Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
ChemMedChem. 2017 Dec 7;12(23):1942-1952. doi: 10.1002/cmdc.201700614. Epub 2017 Nov 24.

引用本文的文献

1
Enthalpic Classification of Water Molecules in Target-Ligand Binding.
J Chem Inf Model. 2024 Aug 26;64(16):6583-6595. doi: 10.1021/acs.jcim.4c00794. Epub 2024 Aug 12.
2
FMO-guided design of darunavir analogs as HIV-1 protease inhibitors.
Sci Rep. 2024 Feb 13;14(1):3639. doi: 10.1038/s41598-024-53940-1.
3
Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors.
Molecules. 2023 Aug 30;28(17):6330. doi: 10.3390/molecules28176330.
4
Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques.
Int J Mol Sci. 2022 Oct 12;23(20):12149. doi: 10.3390/ijms232012149.
5
Effective estimation of the inhibitor affinity of HIV-1 protease a modified LIE approach.
RSC Adv. 2020 Feb 21;10(13):7732-7739. doi: 10.1039/c9ra09583g. eCollection 2020 Feb 18.
6
identification of drug candidates against COVID-19.
Inform Med Unlocked. 2020;21:100461. doi: 10.1016/j.imu.2020.100461. Epub 2020 Oct 20.
8
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1.
9
Synthesis of a Chloroalkene Dipeptide Isostere-Containing Peptidomimetic and Its Biological Application.
ACS Med Chem Lett. 2017 Dec 27;9(1):6-10. doi: 10.1021/acsmedchemlett.7b00234. eCollection 2018 Jan 11.

本文引用的文献

1
Processing of X-ray diffraction data collected in oscillation mode.
Methods Enzymol. 1997;276:307-26. doi: 10.1016/S0076-6879(97)76066-X.
3
Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
J Med Chem. 2006 Aug 24;49(17):5252-61. doi: 10.1021/jm060561m.
4
Synthesis, antiviral activity, and pharmacokinetic evaluation of P3 pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors.
Bioorg Med Chem. 2006 Jun 15;14(12):4035-46. doi: 10.1016/j.bmc.2006.02.013. Epub 2006 Feb 28.
5
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Bioorg Med Chem Lett. 2006 Apr 1;16(7):1788-94. doi: 10.1016/j.bmcl.2006.01.035. Epub 2006 Feb 3.
7
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
J Med Chem. 2005 Mar 24;48(6):1965-73. doi: 10.1021/jm049454n.
8
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
J Med Chem. 2005 Mar 24;48(6):1813-22. doi: 10.1021/jm049560p.
9
Coot: model-building tools for molecular graphics.
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. doi: 10.1107/S0907444904019158. Epub 2004 Nov 26.
10
Combating susceptibility to drug resistance: lessons from HIV-1 protease.
Chem Biol. 2004 Oct;11(10):1333-8. doi: 10.1016/j.chembiol.2004.08.010.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验